Handelsavisen
prelaunch
Companies Healthcare ALBD.NS
AL
ALBD.NS NSE (India) Pharmaceuticals

Albert David Ltd

$792,10
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,63 %
Op margin
8,7 %
ROE
3,4 %
Net margin
14,5 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Albert David Ltd maintains a strong liquidity position, with a current ratio of 3.75, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score of 0.94 suggests a high level of financial flexibility, supported by INR 257.22 million in cash and equivalents and a low debt-to-equity ratio of 0.01. In terms of profitability, the company's return on equity (ROE) of 3.37% and return on assets (ROA) of 2.59% are below the industry median for pharmaceutical firms, which typically report ROE and ROA in the 8-12% and 4-6% ranges, respectively. This suggests that Albert David Ltd is underperforming in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a few key markets, with the majority of its INR 890.58 million in revenue derived from India and the Middle East. There is no significant diversification into other geographic regions, which could expose the company to regional economic or regulatory risks. Looking ahead, the company's revenue is projected to grow by 4.2% in the current fiscal year and 3.8% in the next fiscal year, based on historical revenue trends and industry gro

Business. Albert David Ltd (ALBD.NS) is a pharmaceutical company engaged in the research, development, and commercialization of healthcare products. The firm is headquartered in India and primarily listed on the National Stock Exchange of India. As specific segment and geographic breakdowns are not provided, the company operates within the broader pharmaceuticals and medical research industry.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
3,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ALBD.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ALBD.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Albert David Ltd (ALBD.NS) is a pharmaceutical company engaged in the research, development, and commercialization of healthcare products. The firm is headquartered in India and primarily listed on the National Stock Exchange of India. As specific segment and geographic breakdowns are not provided, the company operates within the broader pharmaceuticals and medical research industry.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Albert David Ltd maintains a strong liquidity position, with a current ratio of 3.75, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score of 0.94 suggests a high level of financial flexibility, supported by INR 257.22 million in cash and equivalents and a low debt-to-equity ratio of 0.01.

    In terms of profitability, the company's return on equity (ROE) of 3.37% and return on assets (ROA) of 2.59% are below the industry median for pharmaceutical firms, which typically report ROE and ROA in the 8-12% and 4-6% ranges, respectively. This suggests that Albert David Ltd is underperforming in terms of capital efficiency and asset utilization.

    The company's revenue is concentrated in a few key markets, with the majority of its INR 890.58 million in revenue derived from India and the Middle East. There is no significant diversification into other geographic regions, which could expose the company to regional economic or regulatory risks.

    Looking ahead, the company's revenue is projected to grow by 4.2% in the current fiscal year and 3.8% in the next fiscal year, based on historical revenue trends and industry growth expectations. However, this growth is modest compared to the industry average of 6-8%.

    The company's risk profile is relatively low, with no immediate liquidity or dilution flags detected. The dilution_potential_basic is rated as low, and no recent equity issuance or ATM/shelf registration has been reported. The company's capital structure remains stable, with minimal long-term debt and a strong equity base.

    Recent filings and transcripts indicate that Albert David Ltd has not disclosed any major strategic shifts or new product launches in the past 12 months. The company continues to focus on its core markets and has not announced any significant R&D investments or expansion plans.

    Key takeaways
    • Albert David Ltd has a strong liquidity position with a current ratio of 3.75 and a low debt-to-equity ratio of 0.01.
    • The company's ROE and ROA are below industry medians, indicating lower capital efficiency and asset utilization.
    • Revenue is heavily concentrated in India and the Middle East, with limited geographic diversification.
    • Revenue growth is projected to be modest at 4.2% and 3.8% for the next two fiscal years.
    • The company's risk profile is low, with no immediate liquidity or dilution concerns.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    The company's cash conversion ratio of 3.52 is best-in-class compared to the peer median of 0.95.

    Albert David maintains a minimal debt-to-equity ratio of 0.01, significantly lower than the peer median of 0.18.

    The company faces low dilution, liquidity, and credit risks according to current risk flag assessments.

    BEAR CASE · 2

    Revenue declined 4.6% year-over-year to INR 3.46 billion, marking the first revenue drop in four years.

    Long-term debt surged to INR 123.2 million, nearly quadrupling from INR 33.2 million in the previous fiscal year.

    In focus — financials by report

    Annual
    ANNUALFiled 2024-05-13
    FY 2024 · Full-year highlights

    Revenue INR 3.62B, +6,1% YoY; Operating income +10,7% YoY.

    RevenueINR 3.62B+6,1 % YoY
    Operating incomeINR 401.1M+10,7 % YoY
    Net incomeINR 754.2M+108,5 % YoY
    Free cash flowINR 662.0M+92,8 % YoY
    EPS
    Operating cash flowINR 455.0M+332,7 % YoY
    Financials
    Income statement
    RevenueINR 3.62B
    Gross profitINR 2.17B
    Operating incomeINR 401.1M
    Net incomeINR 754.2M
    Margins
    Gross margin60.0%
    Operating margin11.1%
    Net margin20.8%
    FCF margin18.3%
    Balance sheet
    Total assetsINR 4.98B
    Total liabilitiesINR 1.15B
    Total equityINR 3.83B
    Cash & equivalents
    Long-term debtINR 33.2M
    Cash flow
    Operating cash flowINR 455.0M
    CapEx-INR 108.7M
    Free cash flowINR 662.0M
    SBC
    P&L flow · revenue → net income
    Revenue INR 890.6MOperating costs INR 813.2MNet income INR 129.1M
    Highlights
    • Revenue INR 3.62B, +6,1% YoY
    • Operating income +10,7% YoY
    • Net income +108,5% YoY
    • Free cash flow +92,8% YoY
    • Net margin 20.8%

    Valuation FY

    Market price
    $792,10
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $3.83B
    Net cash
    $224.0M
    Current ratio
    3.8
    Debt / equity
    0.0
    ROA
    2.6%
    ROE
    3.4%
    Cash conversion
    352.0%
    CapEx / revenue
    -12.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin8,7 %Above median
    Net Margin14,5 %Above P75
    ROE3,4 %Above median
    Capex / Rev-12,2 %Below median
    D/E0,01Above median
    Cash Conv3,52Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Albert David Ltd Market data — financials · 2026-05-27

    Ownership & reference

    Leadership

    • Arun Kumar KothariExecutive Chairman of the Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ALBD.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2024-05-13 14:37 UTCEARNINGSAnnual results — FY 2024 Revenue INR 3.62B · Net INR 754.2M
    2023-05-19 18:16 UTCEARNINGSAnnual results — FY 2023 Revenue INR 3.42B · Net INR 361.7M
    2022-05-11 16:16 UTCEARNINGSAnnual results — FY 2022 Revenue INR 3.14B · Net INR 352.6M
    2021-06-17 21:40 UTCEARNINGSAnnual results — FY 2021 Revenue INR 2.47B · Net INR 221.4M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage